TW201930269A - 用於治療cns病症之組合物及方法 - Google Patents

用於治療cns病症之組合物及方法 Download PDF

Info

Publication number
TW201930269A
TW201930269A TW108101261A TW108101261A TW201930269A TW 201930269 A TW201930269 A TW 201930269A TW 108101261 A TW108101261 A TW 108101261A TW 108101261 A TW108101261 A TW 108101261A TW 201930269 A TW201930269 A TW 201930269A
Authority
TW
Taiwan
Prior art keywords
substituted
unsubstituted
group
compound
alkyl
Prior art date
Application number
TW108101261A
Other languages
English (en)
Chinese (zh)
Inventor
艾伯特 J 羅比喬德
法藍西司科 G 薩突羅
佩拉杜 馬利亞 耶稣 巴蘭可
丹尼爾 拉
柏伊德 L 哈里森
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW201930269A publication Critical patent/TW201930269A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/006—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by sulfur as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C07J75/005—Preparation of steroids by cyclization of non-steroid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
TW108101261A 2018-01-12 2019-01-11 用於治療cns病症之組合物及方法 TW201930269A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862616768P 2018-01-12 2018-01-12
US201862617134P 2018-01-12 2018-01-12
US62/617,134 2018-01-12
US62/616,768 2018-01-12
US201862728514P 2018-09-07 2018-09-07
US62/728,514 2018-09-07

Publications (1)

Publication Number Publication Date
TW201930269A true TW201930269A (zh) 2019-08-01

Family

ID=65324563

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108101261A TW201930269A (zh) 2018-01-12 2019-01-11 用於治療cns病症之組合物及方法

Country Status (6)

Country Link
US (3) US11718642B2 (https=)
EP (2) EP4706761A3 (https=)
JP (3) JP7538040B2 (https=)
MA (1) MA51568A (https=)
TW (1) TW201930269A (https=)
WO (1) WO2019140272A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111233815A (zh) * 2020-01-21 2020-06-05 上海应用技术大学 一种异阿根廷蚁素的制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
TW201930269A (zh) 2018-01-12 2019-08-01 美商賽吉醫療公司 用於治療cns病症之組合物及方法
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
KR20220112803A (ko) * 2019-12-05 2022-08-11 세이지 테라퓨틱스, 인크. 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP4125921A1 (en) 2020-03-25 2023-02-08 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE69435286D1 (de) 1993-05-24 2010-05-20 Purdue Pharma Ltd Verfahren und zusammensetzungen zum hervorrufen von schlaf
NZ298567A (en) * 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
ATE284895T1 (de) 1995-06-06 2005-01-15 Euro Celtique Sa Neuroaktive steroide der androstan- und pregnanreihe
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
BR112020012761A2 (pt) 2017-12-22 2021-02-17 Sage Therapeutics, Inc. composições e métodos para o tratamento de distúrbios do snc
TW201930269A (zh) 2018-01-12 2019-08-01 美商賽吉醫療公司 用於治療cns病症之組合物及方法
WO2019154257A1 (zh) 2018-02-11 2019-08-15 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
CN109503694A (zh) 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
KR20250174100A (ko) 2018-12-05 2025-12-11 세이지 테라퓨틱스, 인크. 신경활성 스테로이드 및 이의 사용 방법
CN113272315B (zh) 2018-12-26 2023-08-08 张家口华健致远生物科技有限公司 一类类固醇化合物及其用途
WO2021188778A2 (en) 2020-03-18 2021-09-23 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111233815A (zh) * 2020-01-21 2020-06-05 上海应用技术大学 一种异阿根廷蚁素的制备方法
CN111233815B (zh) * 2020-01-21 2022-10-14 上海应用技术大学 一种异阿根廷蚁素的制备方法

Also Published As

Publication number Publication date
US12421275B2 (en) 2025-09-23
JP2025106370A (ja) 2025-07-15
JP2021510695A (ja) 2021-04-30
US20240150393A1 (en) 2024-05-09
EP4706761A3 (en) 2026-05-06
US20200354399A1 (en) 2020-11-12
EP3737687A1 (en) 2020-11-18
US20260078143A1 (en) 2026-03-19
JP2023145726A (ja) 2023-10-11
EP4706761A2 (en) 2026-03-11
JP7538040B2 (ja) 2024-08-21
US11718642B2 (en) 2023-08-08
JP7817214B2 (ja) 2026-02-18
EP3737687B1 (en) 2025-10-22
MA51568A (fr) 2021-04-21
WO2019140272A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
TW201930269A (zh) 用於治療cns病症之組合物及方法
US12473327B2 (en) Neuroactive steroids, compositions and uses thereof
JP7569412B2 (ja) ＣＮＳ障害を処置するためのジュウテリウム化された２１－［４－シアノ－ピラゾール－１－イル］－１９－ノル－プレガン－３．α－オール－２０－オン誘導体
TWI835765B (zh) 用於治療cns病症之組合物及方法
JP7692830B2 (ja) ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物
TWI835884B (zh) 神經活性類固醇及其使用方法
JP2024114787A (ja) Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
TWI896548B (zh) 用於治療cns病症之組合物及方法
TW202143976A (zh) 神經活性類固醇及其使用方法
TW202233198A (zh) 神經活性類固醇及其組合物
TW202114700A (zh) 用於治療cns病症之組合物及方法
TW202027754A (zh) 神經活性類固醇及其使用方法
TW202612704A (zh) 用於治療cns病症之組合物及方法